CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
ONK Therapeutics
Main focus: Next-generation cell therapies for the treatment of cancer
Company stage: Pre-clinical
Diseases (gene editing): Multiple myeloma (MM), Acute myeloid leukaemia (AML), ovarian cancer, non-small cell lung cancer (NSCLC), breast cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Galway, Republic of Ireland
Website: https://www.onktherapeutics.com/
Pipeline: https://www.onktherapeutics.com/pipeline/
Gene-editing partnerships: Intellia Therapeutics
ONK Therapeutics develops next-generation natural killer (NK) cell-based therapies for the treatment of cancer. The company tries to deploy multiple different knock-outs of different genes using CRISPR-Cas9 in its chimeric antigen receptor NK (CAR-NK) products. While the company is still conducting pre-clinical studies, it has disclosed multiple different haematological and solid tumour types that it will initially target. The company has established a collaboration with Intellia Therapeutics, which gives ONK Therapeutics non-exclusive rights to the CRISPR-Cas9 system and lipid nanoparticle (LNP) delivery technologies.
